Our Mission
The Oxford Vaccine Group has been at the forefront of vaccine development for 30 years, helping to fight diseases of major global importance through research and education around the world.
What's Happening?
Study Spotlight
🌍 Malaria remains a global health challenge with 240 million cases and 627,000 deaths in 2020. But we're on a mission to change this. Learn more about our groundbreaking malaria challenge study below. Let's eradicate malaria together!
Bio001👤 18-45 years 📅 Between 19 and 20 visits over 19 months 💉 3 vaccinations +/- Lymph node sampling 🧬 A trial to assess the safety and effectiveness of two malaria vaccines 🪙 Between £1,880 - £2,030 reimbursement (depending on Group) |
Be a Vaccine Hero
Take part in a study
Could you be a Vaccine Hero by taking part in one of our clinical trials? Find out about the trials and studies currently looking for volunteers, as well as what it is like taking part from previous participants.
Study - NIV001
Our phase I safety and immunogenicity trial of a Nipah virus vaccine, ChAdOx1 NipahB, is looking for healthy volunteers aged 18-55 years in the UK to help investiage a vaccine against this WHO priority disease.
Study - 6-in-1 part 2
A children's study which will guide decisions on future changes to the routine UK immunisation schedule. Two optional doses of a vaccine which helps to prevent chickenpox will be offered in visits to the participants own home.
Study - BIO-004
We are looking for volunteers aged from 18 to 45 years old to take part in a challenge study to investigate how the immune system responds to repeated malaria infection. We will reimburse you up to £9,100 for your time, inconvenience, and travel.
Research at OVG
Education, Learning and Public Involvement
Latest Publications
⠀⠀⠀⠀⠀
-
Development and preclinical analysis of lipopolysaccharide-based glycoconjugate vaccine candidates against Coxiella burnetti
Thesis / Dissertation
Zhu H., (2024)
-
Journal article
Dinh Thiem V. et al, (2024), Vaccine
-
Journal article
Jackson S. et al, (2024), Lancet Microbe
-
Journal article
Clemens SAC. et al, (2024), Frontiers in Public Health, 12